MAXALT 5 MG — DIN 02240520
RIZATRIPTAN (RIZATRIPTAN BENZOATE) : 5 MG · MERCK CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is MAXALT?
MAXALT 5 MG contains RIZATRIPTAN (RIZATRIPTAN BENZOATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02240520, held by MERCK CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 15-Jul-2013. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is MAXALT used for?
MAXALT ® (rizatriptan benzoate) is indicated for: acute treatment of migraine attacks with or without aura in adults. MAXALT ® is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of MAXALT ® have not been established for cluster headache.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Rizatriptan cost around the world?
Rizatriptan is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 47 | USD███.██ |
| Sweden | AIP (pharmacy purchase price) | 11 | 43 | SEK███.██ |
| Italy | prezzo al pubblico (classe A) | 17 | 26 | EUR███.██ |
| South Africa | single exit price | 11 | 17 | ZAR███.██ |
| Australia | ex-manufacturer | 7 | 7 | AUD███.██ |
| United Kingdom | hospital | 6 | 6 | GBP███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| Iceland | max wholesale | 2 | 4 | ISK███.██ |
| Spain | PVP con IVA (public price) | 3 | 3 | EUR███.██ |
159 pack listings across 67 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Rizatriptan pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Rizatriptan in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
30 holders have a Canadian DIN containing Rizatriptan, across 85 DINs, of which 34 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 6 | 3 | JAMP RIZATRIPTAN, JAMP-RIZATRIPTAN IR, JAMP-RIZATRIPTAN ODT | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 6 | 3 | IPG-RIZATRIPTAN, MAR-RIZATRIPTAN, MAR-RIZATRIPTAN ODT | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 3 | ACT RIZATRIPTAN, TEVA-RIZATRIPTAN, TEVA-RIZATRIPTAN ODT | Sourceable in Canada |
| MANTRA PHARMA INC | 4 | 3 | M-RIZATRIPTAN, M-RIZATRIPTAN ODT | Sourceable in Canada |
| SANIS HEALTH INC | 4 | 3 | RIZATRIPTAN, RIZATRIPTAN ODT | Sourceable in Canada |
| ORGANON CANADA INC. | 3 | 3 | MAXALT, MAXALT RPD | Sourceable in Canada |
| APOTEX INC | 4 | 2 | APO-RIZATRIPTAN, APO-RIZATRIPTAN RPD | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 4 | 2 | MYLAN-RIZATRIPTAN, MYLAN-RIZATRIPTAN ODT | Sourceable in Canada |
| ACCEL PHARMA INC | 2 | 2 | ACCEL-RIZATRIPTAN ODT | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 2 | PMS-RIZATRIPTAN RDT | Sourceable in Canada |
| PRO DOC LIMITEE | 2 | 2 | RIZATRIPTAN RDT | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 2 | SANDOZ RIZATRIPTAN ODT | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Rizatriptan |
|---|---|
| ATC code | N02CC04 |
| AHFS class | 28:32.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02240520 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2240520 |
| Brand name | MAXALT |
| Generic / active ingredient | RIZATRIPTAN (RIZATRIPTAN BENZOATE) : 5 MG |
| Market authorization holder | MERCK CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | N02CC04 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02CC |
| Current status | CANCELLED POST MARKET |
| Status date | 15-Jul-2013 |
| Original market date | 1999-08-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
34 of 85 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-RIZATRIPTAN ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | 02483289 |
| ACCEL-RIZATRIPTAN ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | 02483270 |
| ACT RIZATRIPTAN | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02381702 |
| AG-RIZATRIPTAN ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | ANGITA PHARMA INC. | MARKETED | 02492482 |
| AG-RIZATRIPTAN ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | ANGITA PHARMA INC. | MARKETED | 02492490 |
| APO-RIZATRIPTAN | 5 MG | TABLET | APOTEX INC | MARKETED | 02393468 |
| APO-RIZATRIPTAN | 10 MG | TABLET | APOTEX INC | MARKETED | 02393476 |
| JAMP RIZATRIPTAN | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02380463 |
| JAMP-RIZATRIPTAN ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | JAMP PHARMA CORPORATION | MARKETED | 02465094 |
| JAMP-RIZATRIPTAN ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | JAMP PHARMA CORPORATION | MARKETED | 02465086 |
2 · Same class — other molecules in ATC N02CC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Rizatriptan | ACCEL-RIZATRIPTAN ODT · ACT RIZATRIPTAN · ACT RIZATRIPTAN ODT · AG-RIZATRIPTAN ODT · +36 more | 85 | 34 | Yes |
| Sumatriptan | ACT SUMATRIPTAN · AG-SUMATRIPTAN · APO-SUMATRIPTAN · AVA-SUMATRIPTAN · +27 more | 80 | 32 | Yes |
| Eletriptan | APO-ELETRIPTAN · APO-ELETRIPTAN TABLETS · AURO-ELETRIPTAN · ELETRIPTAN · +6 more | 20 | 16 | Yes |
| Zolmitriptan | AG-ZOLMITRIPTAN ODT · APO-ZOLMITRIPTAN · APO-ZOLMITRIPTAN RAPID · AURO-ZOLMITRIPTAN · +33 more | 45 | 15 | Yes |
| Almotriptan | ALMOTRIPTAN · APO-ALMOTRIPTAN · AXERT 12.5MG · AXERT 6.25MG · +5 more | 13 | 6 | Yes |
| Frovatriptan | APO-FROVATRIPTAN · FROVA · FROVATRIPTAN · JAMP FROVATRIPTAN · +2 more | 6 | 5 | Yes |
| Naratriptan | AMERGE · APO-NARATRIPTAN · SANDOZ NARATRIPTAN · TEVA-NARATRIPTAN | 7 | 3 | Yes |
| Sumatriptan And Naproxen | SUVEXX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02CD | Atogepant · Eptinezumab · Erenumab · Fremanezumab · Galcanezumab · +2 more | 17 | 15 |
| N02CA | Dihydroergotamine · Ergotamine · Ergotamine, Combinations Excl. Psycholeptics · Ergotamine, Combinations With Psycholeptics · Methysergide | 15 | 2 |
| N02CX | Clonidine · Pizotifen | 3 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MAXALT called?
The same molecule, Rizatriptan, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Rizatriptan Glenmark | Latin | Sweden |
| Rizatriptan Ebb | Latin | Sweden |
| Rizatriptan STADA | Latin | Sweden |
| Maxalt® | Latin | Sweden |
| Maxalt® Rapitab® | Latin | Sweden |
| Rizasmelt | Latin | Sweden |
| Rizatriptan Alvogen | Latin | Iceland |
| Rizatriptan Abacus Medicine | Latin | Sweden |
| APO-RIZATRIPTAN ODT | Latin | Australia |
| Maxalt Smelt | Latin | Iceland |
| RIXALT | Latin | Australia |
| Rizagran OTC | Latin | South Africa |
| Rizatriptan ODT Viatris | Latin | Australia |
| RIZATRIPTAN ODT-WGR | Latin | Australia |
| Rizatriptan Sandoz | Latin | Sweden |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.